Loading...
Loading...
ICPT| Name | Value |
|---|---|
| Revenues | 77.6M |
| Cost of Revenue | 0.4M |
| Gross Profit | 77.2M |
| Operating Expense | 87.3M |
| Operating I/L | -10.1M |
| Other Income/Expense | -93.9M |
| Interest Income | 0.0M |
| Pretax | -104.1M |
| Income Tax Expense | -277.6M |
| Net Income/Loss | 173.5M |
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company specializing in therapeutics for progressive non-viral liver diseases. Its flagship product, Ocaliva, is a treatment for primary biliary cholangitis. The company also develops Ocaliva for nonalcoholic steatohepatitis and other indications, along with other product candidates in clinical and preclinical stages. Intercept markets its products through an internal commercial organization and third-party distributors, generating revenue from the sales of Ocaliva and potential future products.
